| Name | Title | Contact Details |
|---|
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Southern Research Institute is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioXcel is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.